Study In Patients With Kidney Cancer Treated With Sutent
NCT ID: NCT00873210
Last Updated: 2012-11-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
121 participants
OBSERVATIONAL
2009-05-31
2011-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients treated with Sutent
125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
Sutent
50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sutent
50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any other contraindication to the use of sunitinib malate (based on decision of the treating physician).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Banská Bystrica, , Slovakia
Pfizer Investigational Site
Bojnice, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Bratislava, , Slovakia
Pfizer Investigational Site
Košice, , Slovakia
Pfizer Investigational Site
Michalovce, , Slovakia
Pfizer Investigational Site
Nitra, , Slovakia
Pfizer Investigational Site
Poprad, , Slovakia
Pfizer Investigational Site
Prešov, , Slovakia
Pfizer Investigational Site
Ružomberok, , Slovakia
Pfizer Investigational Site
Trebišov, , Slovakia
Pfizer Investigational Site
Trenčín, , Slovakia
Pfizer Investigational Site
Trnava, , Slovakia
Pfizer Investigational Site
Žilina, , Slovakia
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A6181185
Identifier Type: -
Identifier Source: org_study_id